Hirudoid 40000 iu cream for phlebitis and edema 50g

Product Description

Hirudoid Dermatological Cream 40000 IU

Composition:

Active ingredient per 100 g of cream: glycosaminoglycan polysulfate (M.W. 5700–13700) mg 445 equal to 40000 IU.

Excipients

Excipients per 100 g of cream: Cutin LE; medium-chain triglycerides; myristic alcohol; isopropyl myristate; bentonite; perfumed essence; isopropyl alcohol; imidurea; phenoxyethanol; rosemary oil.

Therapeutic indications

Thrombophlebitis and superficial phlebitis. Venous stasis edema. Pain, inflammation, edema, trophic disorders in post-phlebitic and varicose conditions. Hematomas.

Contraindications

Hypersensitivity to the active substance, to a heparinoid or to any of the excipients listed in paragraph 6.1.

Dosage

Puncture the membrane of the tube with the capsule pin. Cream: Unless otherwise prescribed, apply 3–5 cm of cream to the affected area 2–3 times a day (more if necessary and during initial applications) and massage lightly until the cream is absorbed. In the case of particularly painful inflammation and in the presence of thrombosis, carefully spread Hirudoid 40,000 IU cream over the entire affected skin area and also around it, and cover with cotton gauze or similar. In these cases, the therapeutic effect of Hirudoid 40,000 IU cream can be amplified by rubbing even areas further away from the affected area.

Warnings and precautions

External use; if sensitization occurs, which can arise with prolonged use of products for skin application, treatment should be discontinued. Hirudoid 40,000 IU cream contains alcohol among the excipients and therefore should not be applied to open wounds or mucous membranes.

Interactions

No particular interactions with other medicinal products have been reported.

Side effects

No particular side effects have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.

Pregnancy and breastfeeding

There are no special precautions or warnings for the product in case of pregnancy and breastfeeding.